WallStreetZenWallStreetZen

NASDAQ: XERS
Xeris Biopharma Holdings Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for XERS

Based on 6 analysts offering 12 month price targets for Xeris Biopharma Holdings Inc

Min Forecast
$4.00-13.79%
Avg Forecast
$6.25+34.7%
Max Forecast
$8.00+72.41%

Should I buy or sell XERS stock?

Based on 6 analysts offering ratings for Xeris Biopharma Holdings Inc.

Buy
Strong Buy
1 analysts 16.67%
Buy
4 analysts 66.67%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although XERS's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates XERS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their XERS stock forecasts and price targets.

XERS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-09
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2025-03-07
lockedlocked$00.00+00.00%2025-03-07
Jefferies
Top 32%
69
Strong BuyReiterates$6.00+29.31%2025-01-29

1 of 1

Forecast return on equity

Is XERS forecast to generate an efficient return?

Company
-252.26%
Industry
145.33%
Market
89.41%
XERS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is XERS forecast to generate an efficient return on assets?

Company
28.09%
Industry
32.94%
XERS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

XERS earnings per share forecast

What is XERS's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.08
Avg 2 year Forecast
$0.05
Avg 3 year Forecast
$0.34

XERS revenue forecast

What is XERS's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$268.3M+20.56%
Avg 2 year Forecast
$322.8M+45.03%
Avg 3 year Forecast
$369.7M+66.1%
XERS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

XERS revenue growth forecast

How is XERS forecast to perform vs Biotechnology companies and vs the US market?

Company
18.56%
Industry
56.67%
Market
9.77%
XERS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
XERS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

XERS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
XERS$4.64$6.25+34.70%Buy
GYRE$7.77N/AN/A
IMNM$8.74$27.75+217.51%Strong Buy
GHRS$11.68$29.67+154.00%Strong Buy
QURE$13.95$38.00+172.40%Buy
View Top Biotech Stocks

Xeris Biopharma Holdings Stock Forecast FAQ

Is Xeris Biopharma Holdings Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: XERS) stock is to Buy XERS stock.

Out of 6 analysts, 1 (16.67%) are recommending XERS as a Strong Buy, 4 (66.67%) are recommending XERS as a Buy, 1 (16.67%) are recommending XERS as a Hold, 0 (0%) are recommending XERS as a Sell, and 0 (0%) are recommending XERS as a Strong Sell.

If you're new to stock investing, here's how to buy Xeris Biopharma Holdings stock.

What is XERS's earnings growth forecast for 2025-2027?

(NASDAQ: XERS) Xeris Biopharma Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.29%.

Xeris Biopharma Holdings's earnings in 2025 is -$45,076,000.On average, 5 Wall Street analysts forecast XERS's earnings for 2025 to be -$13,453,020, with the lowest XERS earnings forecast at -$22,421,700, and the highest XERS earnings forecast at -$6,406,200. On average, 5 Wall Street analysts forecast XERS's earnings for 2026 to be $8,648,370, with the lowest XERS earnings forecast at -$33,632,550, and the highest XERS earnings forecast at $33,632,550.

In 2027, XERS is forecast to generate $54,132,390 in earnings, with the lowest earnings forecast at $33,632,550 and the highest earnings forecast at $70,468,200.

What is XERS's revenue growth forecast for 2025-2027?

(NASDAQ: XERS) Xeris Biopharma Holdings's forecast annual revenue growth rate of 18.56% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.77%.

Xeris Biopharma Holdings's revenue in 2025 is $222,551,000.On average, 3 Wall Street analysts forecast XERS's revenue for 2025 to be $42,970,066,965, with the lowest XERS revenue forecast at $42,122,366,550, and the highest XERS revenue forecast at $43,514,113,500. On average, 4 Wall Street analysts forecast XERS's revenue for 2026 to be $51,691,948,110, with the lowest XERS revenue forecast at $50,416,794,000, and the highest XERS revenue forecast at $54,548,793,000.

In 2027, XERS is forecast to generate $59,201,616,060 in revenue, with the lowest revenue forecast at $55,974,172,500 and the highest revenue forecast at $66,288,154,500.

What is XERS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: XERS) forecast ROA is 28.09%, which is lower than the forecast US Biotechnology industry average of 32.94%.

What is XERS's Price Target?

According to 6 Wall Street analysts that have issued a 1 year XERS price target, the average XERS price target is $6.25, with the highest XERS stock price forecast at $8.00 and the lowest XERS stock price forecast at $4.00.

On average, Wall Street analysts predict that Xeris Biopharma Holdings's share price could reach $6.25 by May 9, 2026. The average Xeris Biopharma Holdings stock price prediction forecasts a potential upside of 34.7% from the current XERS share price of $4.64.

What is XERS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: XERS) Xeris Biopharma Holdings's current Earnings Per Share (EPS) is -$0.30. On average, analysts forecast that XERS's EPS will be -$0.08 for 2025, with the lowest EPS forecast at -$0.14, and the highest EPS forecast at -$0.04. On average, analysts forecast that XERS's EPS will be $0.05 for 2026, with the lowest EPS forecast at -$0.21, and the highest EPS forecast at $0.21. In 2027, XERS's EPS is forecast to hit $0.34 (min: $0.21, max: $0.44).

What is XERS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: XERS) forecast ROE is -252.26%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.